John Clancy
Vice President of Clinical Research, Cystic Fibrosis Foundation · University of Colorado School of Medicine
Credentials: · · ·
History
- Present
Cystic Fibrosis Foundation · University of Colorado School of Medicine
Pulmonary Disease
Internal Medicine
Research
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation
New England Journal of Medicine · 2010 · 629 citations
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease
Neurology · 2007 · 620 citations
Thorax · 2012 · First of 30 authors · Corresponding · 420 citations

37 papers
- ES
29 papers

18 papers · 2 as a fellow

16 papers

15 papers

13 papers · 1 as a fellow

13 papers
- DN
12 papers
Grants
- 2018–2023
Personalized Cystic Fibrosis Therapy and Research Center
National Institute of Diabetes and Digestive and Kidney Diseases · P30
PI · $5.8M · Cincinnati Childrens Hosp Med Ctr
- 2018–2021
Preclinical Characterization of Saracatinib for Cystic Fibrosis Therapy
National Center for Advancing Translational Sciences · UG3
PI · $636K · Cincinnati Childrens Hosp Med Ctr
- 2012–2021
Cincinnati Children's Summer Medical Student Respiratory Research Fellowship
National Heart, Lung, and Blood Institute · T35
PI · $352.5K · Cincinnati Childrens Hosp Med Ctr
- 2016–2021
Regional Monitoring of CF Lung Disease After Changes in Mechanical Airway-Clearance Treatment
National Heart, Lung, and Blood Institute · R01
PI · $1.5M · Cincinnati Childrens Hosp Med Ctr
Clinical trials
- 2015–2016
Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation
Principal investigator · Completed · Phase 1
ProQR Therapeutics
- 2013–2019
Comparing Chest Images From MRI to CT in Patients With Cystic Fibrosis (CF)
Principal investigator · Completed
Children's Hospital Medical Center, Cincinnati
- 2013–2017
Using MRI to Observe Lung Changes in Infants With CF Compared to Infants Without CF
Principal investigator · Completed
Children's Hospital Medical Center, Cincinnati
- 2005–2006



